Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6336006 | 1.00 | MMP2 (0.82) | MMP2MMP9 | |
| Trifluoroacetic Acid SCHEMBL6338742 | 0.96 | MMP2 (0.76) | MMP2MMP9 | |
| SCHEMBL6341998 | 0.95 | MMP2 (0.84) | MMP2MMP9 | |
| SCHEMBL6341996 | 0.95 | MMP2 (0.84) | MMP2MMP9 | |
| SCHEMBL6334130 | 0.94 | MMP2 (0.79) | MMP2MMP9 | |
| SCHEMBL6334133 | 0.94 | MMP2 (0.79) | MMP2MMP9 | |
| SCHEMBL6335867 | 0.93 | MMP2 (0.78) | MMP2MMP9 | |
| SCHEMBL6335869 | 0.93 | MMP2 (0.78) | MMP2MMP9 | |
| SCHEMBL6341636 | 0.93 | MMP2 (0.81) | MMP2MMP9 | |
| SCHEMBL6341634 | 0.93 | MMP2 (0.81) | MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030139597-A1 | Novel Cyclic hydroxamic acid as metalloproteinase inhibitors | XUE CHU-BIAO (US) | 2003-07-24 | — | — | US | claimed |
| US-6429213-B1 | ANTIINFLAMMATORY AGENTS, ANTIARTHRITIS AGENTS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-08-06 | — | — | US | claimed |
| EP-1087937-A1 | CYCLIC HYDROXAMIC ACIDS AS METALLOPROTEINASE INHIBITORS | Du Pont Pharmaceuticals Company (US) | 2001-04-04 | — | — | EP | claimed |
| WO-1999065867-A1 | CYCLIC HYDROXAMIC ACIDS AS METALLOPROTEINASE INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 1999-12-23 | — | — | WO | claimed |
| US-6858626-B2 | Enzyme inhibitor; antiinflammatory agents; osteoporosis | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-02-22 | — | — | US | disclosed |
| US-20030139597-A1 | Novel Cyclic hydroxamic acid as metalloproteinase inhibitors | XUE CHU-BIAO (US) | 2003-07-24 | — | — | US | disclosed |
| US-6429213-B1 | ANTIINFLAMMATORY AGENTS, ANTIARTHRITIS AGENTS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139597-A1 | Novel Cyclic hydroxamic acid as metalloproteinase inhibitors | MMP9, MMP2, MMP25 | MMP2 2/4885MMP9 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.